A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
- Registration Number
- NCT00455507
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Brief Summary
The purpose of this study is to establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with advanced Parkinson's disease (PD) treated with levodopa.
- Detailed Description
To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with advanced Parkinson's disease (PD) treated with levodopa. Patients who meet entry criteria will be randomized in a 1:1:1 ratio to double blind treatment with oral doses of 20 or 40mg/day istradefylline or matching placebo. Patients will be treated for 12 weeks and will have interim visits and end of treatment visit to assess the efficacy and safety of istradefylline.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 363
- UK Parkinson's Disease Society (UKPDS) brain bank criteria (Step 1 and 2) for PD.
- PD stages 2-4 in the OFF state for Modified Hoehn and Yahr Scale.
- On levodopa/dopa-decarboxylase inhibitor for at least one year.
- Taking at least three doses and >=300mg of levodopa per day for at least four weeks before randomization.
- Predictable end of dose wearing off.
- Able to satisfactorily complete Hauser based 24-hour patient Parkinson's diary.
- Have an average of two hours of OFF time on 24-hour diaries.
- On a stable regimen of any other anti-Parkinson's drugs for at least four weeks before randomization.
- Be at least 20 years of age.
- Be willing and able to give written informed consent.
- Taking any excluded medications.
- Neurosurgical treatment or Transcranial Magnetic Stimulation for PD.
- Diagnosis of cancer within 5 years.
- Diagnosis of clinically significant illness of any organ system.
- Diagnosis of dementia or mini-mental status examination score of 25 or less.
- History of drug or alcohol abuse or dependence within the past two years.
- History of psychosis.
- Significant drug allergies.
- Taking anticonvulsants for seizures.
- History of neurological malignant syndrome.
- Pregnant or lactating females.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 3 Placebo Two placebo tablets once daily for 12 weeks 1 Istradefylline 20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks) 2 Istradefylline 40mg KW-6002 per day (two 20 mg KW-6002 tablets orally once daily for 12 weeks)
- Primary Outcome Measures
Name Time Method To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with Parkinson's disease (PD) treated with levodopa/dopa-decarboxylase inhibitor. Last Visit
- Secondary Outcome Measures
Name Time Method To evaluate the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean percentage of awake time per day spent in the OFF state. Every Visit To evaluate mean change in the total hours and the percentage of awake time per day spent in the ON state (without dyskinesia, with dyskinesia, with non-troublesome dyskinesia, and with troublesome dyskinesia). Every Visit To evaluate the change in Unified Parkinson's Disease Rating Scale (UPDRS). Every Visit To evaluate change in the Clinical Global Impression - Improvement scale (CGI-I). Visit 4 and Last Visit To evaluate the safety of 20 mg/day and 40mg/day doses of istradefylline Every Visit